---
title: Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)
nct_id: NCT01952600
overall_status: COMPLETED
sponsor: Arbor Research Collaborative for Health
study_type: OBSERVATIONAL
primary_condition: Chronic Kidney Disease
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01952600.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01952600"
ct_last_update_post_date: 2016-09-20
last_seen_at: "2026-05-12T07:19:37.814Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)

**NCT ID:** [NCT01952600](https://clinicaltrials.gov/study/NCT01952600)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 215
- **Lead Sponsor:** Arbor Research Collaborative for Health
- **Collaborators:** University of Michigan, Henry Ford Health System, National Kidney Foundation, United States, American Association of Kidney Patients, Patient-Centered Outcomes Research Institute
- **Conditions:** Chronic Kidney Disease
- **Start Date:** 2013-06
- **Completion Date:** 2015-12
- **CT.gov Last Update:** 2016-09-20

## Brief Summary

The EPOCH-RRT study seeks to fill knowledge gaps by gaining more understanding of chronic kidney disease (CKD) patients' priorities; assessing the comparative benefits of hemodialysis (HD) versus peritoneal dialysis (PD), with respect to these priorities; and providing tailored information to assist patients with identifying the best dialysis modality fit for their own unique circumstances and perspectives.

The outcomes most relevant to patients ("patient-centered") extend beyond those traditionally assessed in clinical research, with the relative importance varying across patient groups. A tailored decision aid based on these findings can improve patient decision-making processes regarding choice of dialysis modality.

## Detailed Description

Empowering Patients On Choices for Renal Replacement Therapy (EPOCH-RRT)study seeks to identify factors that matter the most to patients with kidney disease and study how they are impacted by different types of dialysis. The inclusion of patients, caregivers, and patient advocacy organizations as research partners will assure that the study addresses questions of greatest relevance to patients facing the need for dialysis.

Aim One of EPOCH-RRT identifies outcomes that are most important to different groups of advanced CKD and dialysis patients through qualitative methods applied for conducting in-depth interviews.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Individuals 18 years of age or older.
* Individuals with advanced chronic kidney disease or on dialysis (in-center, hemodialysis, or peritoneal dialysis) for at least three months.

Exclusion Criteria:

* Individuals under 18 years of age.
* Individuals unable to provide informed consent.
* Individuals who do not have chronic kidney disease.
```

## Arms

- **Chronic Kidney Disease (CKD)** — Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
- **Hemodialysis (HD)** — Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
- **Peritoneal Dialysis (PD)** — Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.

## Primary Outcomes

- **Factors That Are Most Important to Patients** _(time frame: Baseline)_ — Differences in factors most important to patients were compared across chronic kidney disease, hemodialysis, and peritoneal dialysis patients.

## Locations (1)

- Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.arbor research collaborative for health|ann arbor|michigan|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01952600.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01952600*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*